Erschienen in:
06.07.2022 | Hot Topics
Colchicine linked with risk reduction for myocardial infarction in gout patients: systematic review and meta-analysis
verfasst von:
Huipeng Wan, Linhong Zeng, Ruihai Xiao, Xiaoyi Tang, Yan Shu, Shaochen Shen
Erschienen in:
Zeitschrift für Rheumatologie
|
Ausgabe 6/2022
Einloggen, um Zugang zu erhalten
Abstract
Introduction
This meta-analysis aimed to identify the effect of colchicine on myocardial infarction (MI) in patients with gout.
Methods
In February 2021, a systematic computer-based search was conducted in PubMed, EMBASE, and Cochrane Database of Systematic Reviews. Data on patients with gout that compared colchicine versus others (no use of colchicine) were retrieved. The endpoints were the incidence rate for MI. After testing for heterogeneity between studies, data were aggregated for fixed-effects models when necessary.
Results
Three clinical studies with 3012 patients (colchicine group = 1523, control group = 1489) were finally included in the meta-analysis. Colchicine was associated with a decreased risk for myocardial infarction (pooled odds ratio 0.35, 95% confidence interval 0.23–0.55, p < 0.00001).
Conclusions
Colchicine was effective in reducing the incidence of MI in patients with gout.